Bruker currently holds 910.2
M in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. This firm has a current ratio of 2.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Macroaxis provides unbiased investment recommendation on Bruker that should be used to complement current
analysts and expert consensus on Bruker. Our trade advice engine determines the company's potential to grow exclusively from the perspective of an investors' current risk tolerance and investing horizon.
We determine the current worth of Bruker using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bruker based exclusively on its
fundamental and basic
technical indicators. By analyzing Bruker's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Bruker's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bruker. We calculate exposure to Bruker's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Bruker's related companies.
Bruker Investment Alerts
Bruker investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Bruker performance across your portfolios.Please check all
investment alerts for Bruker
Bruker Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Bruker value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bruker competition to find
correlations between indicators driving the intrinsic value of Bruker.
Bruker Gross Profit
Bruker Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Bruker previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Bruker Gross Profit growth over the last 10 years. Please check Bruker's
gross profit and other
fundamental indicators for more details.
A Deeper Perspective On Bruker
The company reported the previous year's revenue of 1.96
B. Net Income was 157.5
M with profit before overhead, payroll, taxes, and interest of 1000
M.
Margins Breakdown
Bruker profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Bruker itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Bruker profit margins.
| Operating Margin | 11.28 |
| EBITDA Margin | 0.18 |
| Gross Margin | 0.56 |
| Profit Margin | 0.0949 |
Bruker Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 8 years. The previous year's value of Bruker Earnings Before Interest Taxes and Depreciation Amortization EBITDA was 345,426,316. Bruker Average Assets is increasing over the last 8 years. Additionally, Bruker Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. The latest value of Bruker Earnings Before Interest Taxes and Depreciation Amortization USD is 345,426,316. Bruker Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 8 years. The previous year's value of Bruker Earnings Before Interest Taxes and Depreciation Amortization EBITDA was 345,426,316. Bruker Average Assets is increasing over the last 8 years. Additionally, Bruker Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years.
Will Bruker growth be trustworthy after the spike?
Downside deviation is down to 1.59. It may connote a possible volatility fall. Bruker has relatively low volatility with skewness of -0.06 and kurtosis of -0.52. However, we advise all investors to independently investigate Bruker to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.
Our Final Takeaway
While other companies under the medical devices industry are still a bit expensive, Bruker may offer a potential longer-term growth to retail investors. To conclude, as of the 16th of February 2021, we believe Bruker is currently
overvalued. It barely shadows the market and projects
very low probability of bankruptcy in the next two years. However, our final 30 days buy-hold-sell recommendation on the enterprise is
Strong Buy.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Bruker. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
